Dengue Vaccines and Vaccination Status in Peru and Latin America

Vocabulary-style flashcards covering the characteristics of dengue vaccines (CYD-TDV, TAK-003, Butantan-DV), clinical trial results, and the current epidemiological and vaccination status in Latin America and Peru as of 2024.

Dengue

A viral disease caused by the bite of an infected $Aedes\,aegypti$ mosquito, which has shown an increasing burden due to factors like urbanization, warmer climates, and human mobility.

CYD-TDV (Dengvaxia®)

A chimeric live-attenuated tetravalent vaccine developed by Sanofi Pasteur, Inc. using a yellow fever virus backbone, administered in three doses at months $0$, $6$, and $12$.

TAK-003 (Qdenga®)

A tetravalent live-attenuated vaccine developed by Takeda Pharma Ltd using a recombinant DNA technology based on a $DENV-2$ backbone, administered in two doses with a $3$-month interval.

Butantan-DV

A single-dose, recombinant DNA, live-attenuated vaccine developed by Instituto Butantan that showed a global efficacy of $79.6\%$ in a Phase III trial published in $2024$.

Virologically Confirmed Dengue (VCD)

The clinical standard used in vaccine trials to measure the prevention of symptomatic dengue fever confirmed by laboratory testing.

Antibody-dependent enhancement (ADE)

A mechanism that can increase the risk of severe dengue in seronegative individuals who receive the CYD-TDV vaccine, leading to the recommendation that it only be given to those with prior laboratory-confirmed infection.

CYD-TDV FDA Authorization ($2019$)

Authorized for the prevention of dengue (serotypes $1$, $2$, $3$, and $4$) in individuals aged $6$ to $16$ years with laboratory-confirmed previous infection living in endemic areas.

TAK-003 EMA Approval ($2022$)

Approved by the European Medicines Agency for individuals aged $4$ years and older, requiring no previous exposure to the disease or laboratory confirmation.

SAGE (Strategic Advisory Group of Experts)

The WHO advisory group that, in $2023$, recommended the introduction of the TAK-003 vaccine for children aged $6$ to $16$ years in settings with high disease burden and transmission intensity.

EMA-Approved TAK-003 Concomitant Use

The vaccine may be administered simultaneously with vaccines against hepatitis A and yellow fever.

Peru Dengue Serotypes

The four serotypes $DENV-1$, $DENV-2$, $DENV-3$, and $DENV-4$ are present in the country, with $DENV-1$ and $DENV-2$ being the most predominant.

Peru Dengue Statistics ($2024$)

Until epidemiological week $22$, the country recorded $247,243$ cases and $233$ deaths, representing an increase of $82.4\%$ compared to the previous year.

Brazil's Vaccination Program

Started mass vaccination in February $2024$ targeting children aged $10$ to $14$ years, following the acquisition of $6.5$ million doses for the year $2024$.

Argentina's Vaccination Status

Approved TAK-003 in April $2023$; the vaccine is available in the private sector, and a public campaign in endemic regions is planned to start in August $2024$.

PAHO Revolving Fund

The mechanism through which Peru plans to perform the purchase of the TAK-003 vaccine in $2024$, following a request sent to the Pan American Health Organization.

Butantan-DV Composition

Composed of attenuated vaccine viruses for $DENV-1$, $DENV-3$, and $DENV-4$, and a chimeric virus containing $DENV-2$ genes on a $DENV-4$ background.